DNA Damage Response May Drive Biological Aging

Key Points

• Chronic DNA damage response (DDR) signaling may connect several biological mechanisms involved in aging.
• Persistent DDR activation may promote cellular senescence, inflammation, and impaired tissue function.
• The proposed “guardian paradox” suggests that intact tumor-suppressor pathways may become harmful when chronically activated.
• The framework remains a testable research hypothesis, with no validated human intervention or clinical biomarker system.
• For Latest Updates and Findings, Explore All Geriatrics CME Conferences and Online Courses

How Does Chronic DNA Damage Response Contribute to Aging?

DNA damage response (DDR) may play a central role in biological aging, according to a new review published in Aging. The paper proposes that persistent activation of cellular DNA surveillance pathways could connect several established mechanisms of aging, including telomere attrition, mitochondrial dysfunction, epigenetic changes, and transposable-element activity.

In healthy cells, DDR signaling responds temporarily to DNA double-strand breaks, replication stress, and oxidative damage before subsiding after repair. With aging, persistent cellular stress may keep these pathways active.

The proposed model suggests that chronic DDR signaling can stabilize p53 and increase p21 and p16INK4a, promoting cell-cycle arrest and cellular senescence. Senescent cells can release inflammatory factors through the senescence-associated secretory phenotype (SASP), potentially impairing stem-cell function, tissue homeostasis, and contributing to systemic inflammaging.

What Is the “Guardian Paradox” in Aging?

The review describes this process as the “guardian paradox.” Tumor-suppressor pathways protect younger tissues by limiting the growth of damaged or potentially cancerous cells. However, persistent activation of these same protective mechanisms could become detrimental during later life.

The framework identifies 16 candidate tumor-suppressor and negative-regulator axes across three evidence tiers. Key examples include p53/MDM2, p16INK4a/BMI-1, SIRT1/DBC1, telomerase/TRF1, PTEN/PI3K-AKT-mTOR, and NRF2/KEAP1.

The model does not suggest that DDR overactivation independently causes aging. Mitochondrial dysfunction, impaired proteostasis, metabolic changes, and epigenetic alterations could also occur upstream or interact with DDR signaling. Age-related somatic mutations, including those associated with clonal hematopoiesis of indeterminate potential (CHIP), may further influence these processes.

Can DNA Damage Response Become a Therapeutic Target?

The review proposes an Aging Axis Profile (AAP) that could combine proteomic, transcriptomic, epigenomic, senescence, and telomere measurements to assess the functional state of aging-related pathways. However, the AAP remains conceptual and has not undergone clinical validation.

Potential future strategies include carefully modulating chronically activated pathways or restoring declining protective regulators such as SIRT1, FOXO3, NRF2, and Klotho. These approaches remain theoretical or preclinical, with potential oncogenic risks requiring extensive investigation.

For Latest Updates and Findings, Explore All Geriatrics CME Conferences and Online Courses

The authors emphasize longitudinal studies and head-to-head experiments to determine whether persistent DDR activation precedes other aging changes. For clinicians and aging researchers, the framework offers a falsifiable research agenda rather than a therapeutic protocol, highlighting the need for validated biomarkers, mechanistic studies, and long-term safety data before human intervention.

Source:

Aging-US